Predilife S.A. (0GA)
XFRA 
XPAR Primary XFRA Summary
0GA Chart
Predilife S.A. (0GA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Predilife S.A. ever had a stock split?
Predilife S.A. Profile
| Professional Services Industry | Industrials Sector | Mr. Stephane Ragusa CEO | XFRA Exchange | FR0010169920 ISIN |
| FR Country | 18 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Predilife S.A. operates in the healthcare industry, focusing on developing and commercializing medical techniques and mathematical models aimed at disease prevention, specifically in the oncology sector. Since its inception in 2004, the company has been dedicated to enhancing medical predictive capabilities, offering innovative solutions that aim at improving patient outcomes through early detection and prevention. Headquartered in Villejuif, France, Predilife stands out for its commitment to integrating technological advancements with medical practice, thereby contributing to the global fight against some of the most prevalent cancers.
Products and Services
- MammoRisk
This product represents a significant advancement in the field of oncology, providing a personalized breast cancer risk assessment. MammoRisk utilizes a sophisticated algorithm that analyzes a variety of factors including genetic, familial, and personal health information to calculate an individual’s risk of developing breast cancer. This predictive tool aids healthcare providers in making informed decisions regarding screening and preventive measures, potentially enhancing early detection strategies.
- DenSeeMammo
DenSeeMammo is an innovative breast density measurement software that aids radiologists in assessing breast density, a factor known to affect the efficacy of traditional mammograms. By providing a more accurate measurement of breast density, DenSeeMammo improves the identification of individuals at higher risk of developing breast cancer, who may benefit from additional screening options. This software aligns with the growing emphasis on personalized medicine, offering a customizable approach to breast cancer screening.
- Prostate Cancer Risk Prediction Device
Expanding its portfolio beyond breast cancer, Predilife has also developed a medical device aimed at predicting the risk of prostate cancer. Although details about this device are not as extensively provided, its inclusion in Predilife’s product range underscores the company’s dedication to applying its expertise in predictive modeling to various types of cancer. This device likely incorporates similar predictive analytics to assess an individual’s risk, facilitating early intervention and personalized care strategies.
